COVID-19 In Vitro Diagnostic Medical Device - detail

Device identification number

2409

CE Marking

✓Yes

HSC common list (RAT)

×No

Format

Near POC / POC

Physical Support

Cassette, Lateral flow

Target type

Antigen

Specimen

Nasopharyngeal swab

Cross-reactivity (pathogens tested)

Alpha Coronavirus 229E (HCoV-229E), Alpha Coronavirus Nl63 (HCoV-Nl63), Beta Coronavirus HKU1 (HCoV-HKU1), Beta Coronavirus OC43 (HCoV-OC43), Parainfluenza Virus Type 2, Parainfluenza Virus Type 3

Lineages detected

A.23.1, AT.1, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.427 (Epsilon), B.1.429 (Epsilon), B.1.525 (Eta), B.1.526 (Iota), B.1.526.1, B.1.526.2, B.1.616, B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3, B.1.621 (Mu), C.36, C.37 (Lambda), P.1 (Gamma), P.2 (Zeta), P.3 (Theta)

Commercial Status

Commercialised

Last Update

2022-08-24 09:08:01 CET

Comments

The SARS-CoV-2/Influenza A+B/RSV/Adenovirus Antigen Combo Rapid Test (Nasopharyngeal Swab) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus(RSV) and Adenovirus antigens in nasopharyngeal swab specimens from individuals with suspected SARS-CoV-2/ Influenza/ RSV/Adenovirus infection in conjunction with clinical presentation and the results of other laboratory tests. Results are for the detection of SARS-CoV-2, Influenza A+B, RSV and Adenovirus antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out other bacterial/viral infection. The agent detected may not be the definite cause of disease. Negative results do not preclude SARS-CoV-2/ Influenza A+B/RSV/Adenovirus infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, Influenza A+B ,RSV and Adenovirus. The SARS-CoV-2/Influenza A+B/RSV/Adenovirus Antigen Combo Rapid Test is intended for use by trained clinical laboratory personnel.

Assay Type

Immuno-Antigen

Reader Required

No

Subcategory

Validity test kit

Method

Immunoassay

Measurement

Qualitative

Time

15 minutes

Subclass

Sandwich

LOD

100 AU

Calibration

Evaluated

Analysis of cross reactivity

Evaluated

False positives

0.032 AU ((Adenovirus))

False positives

0.023 AU ((SARS-CoV-2),)

False positives

0.051 AU ((RSV),)

False positives

0.054 AU ((Influenza Type B),)

False positives

0.03 AU ((Influenza Type A),)

False negatives

0.006 AU ((Influenza Type A),)

False negatives

0.015 AU ((Adenovirus))

False negatives

0.016 AU ((RSV),)

False negatives

0.006 AU ((Influenza Type B),)

False negatives

0.01 AU ((SARS-CoV-2),)

Precision

Evaluated

Accuracy

98.3 % (Antigen)(Adenovirus).)

Accuracy

99.2 % ((Antigen)(Influenza Type A);)

Accuracy

98.6 % ((Antigen)(SARS-CoV-2);)

Accuracy

99 % ((Antigen)(Influenza Type B);)

Accuracy

97.9 % ((Antigen)(RSV);)

Reproducibility

Evaluated

Robustness

Evaluated

Clinical Sensitivity

97.7 % ((Antigen)(SARS-CoV-2);)

Clinical Sensitivity

97 % ((Antigen)(Influenza Type A);)

Clinical Sensitivity

94.6 % ((Antigen)(Influenza Type B);)

Clinical Sensitivity

94.9 % ((Antigen)(RSV);)

Clinical Sensitivity

96.8 % ((Antigen)(Adenovirus).)

Clinical Specificity

99 % ((Antigen)(SARS-CoV-2);)

Clinical Specificity

99.4 ((Antigen)(Influenza Type A);)

Clinical Specificity

99.4 ((Antigen)(Influenza Type B);)

Clinical Specificity

98.4 (Antigen)(RSV);)

Clinical Specificity

98.5 ((Antigen)(Adenovirus).)

Type of antigen

Nucleoprotein